XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders’ Equity [Abstract]  
Schedule of Changes in Options A summary of the changes in options during the nine months ended September 30, 2024 is as follows:
   Number of
Options
   Weighted
Average
Exercise
Price Per
Share
   Weighted
Average
Remaining
Contractual
Term
(Years)
   Aggregate
Intrinsic
Value
 
Outstanding and expected to vest at December 31, 2023   17,416,192   $12.99    8.3   $11,183,370 
Granted   487,434   $3.10    9.63   $
-
 
Exercised   (74,999)  $
-
    -    - 
Forfeited   (18,407)  $
-
    -   $
-
 
Cancelled   (4,757,628)  $
-
    -   $
-
 
Outstanding at September 30, 2024   13,052,592   $16.47    7.02   $599,973 
Options exercisable at September 30, 2024   8,888,189   $19.28    6.52   $111,698 
Schedule of the Changes in Outstanding Warrants A summary of the changes in outstanding warrants during the nine months ended September 30, 2024 is as follows:
   Number of
Shares
   Weighted
Average
Exercise
Price Per
Share
 
Outstanding at December 31, 2023   2,381,366   $20.02 
Forfeited   (717,915)  $
-
 
Exercised   
-
   $
-
 
Outstanding at September 30, 2024   1,663,451   $25.31 
Warrants vested at September 30, 2024   1,600,326   $25.05 
Schedule of Stock-based Compensation Expense The following table summarizes the components of stock-based compensation expense which includes stock options and warrants in the unaudited consolidated statements of operations for the nine months ended September 30, 2024 and 2023 (rounded to nearest $00):
   Nine Months
Ended
September 30,
2024
   Nine Months
Ended
September 30,
2023
 
Research and development  $5,007,300   $5,463,100 
General and administrative   18,450,700    28,453,800 
Total  $23,458,000   $33,916,900